Global Competent Cells Market

1 INTRODUCTION OF GLOBAL COMPETENT CELLS MARKET
1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET INTELLIGENCE
3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL COMPETENT CELLS MARKETOUTLOOK
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis
4.5 Regulatory Framework

5 GLOBAL COMPETENT CELLS MARKET, BY APPLICATION:
5.1 Cloning
5.1.1 Subcloning& Routine Cloning
5.1.2 Phage Display Library Construction
5.1.3 Toxic/Unstable DNA Cloning
5.1.4 High-Throughput Cloning
5.2 Protein Expression
5.3 Others
5.3.1 Mutagenesis
5.3.2 Large Plasmid Transformation
5.3.3 Single-Stranded DNA Production
5.3.4 Lentiviral Vector Production

6 GLOBAL COMPETENT CELLS MARKET, BY TYPE:
6.1 Chemically Competent Cells
6.2 Electro competent Cells

7 GLOBAL COMPETENT CELLS MARKET, BY END USER:
7.1 Academic Research Institutes
7.2 Pharmaceutical & Biotechnology Companies
7.3 Contract Research Organizations

8 GLOBAL COMPETENT CELLS MARKET, BY GEOGRAPHY
8.1 Overview
8.2 North AmericaRegional Market Estimates and Forecasts, 2012 - 2025
8.2.1 U.S.
8.2.2 Canada
8.2.3 Mexico
8.3 EuropeRegional Market Estimates and Forecasts, 2012 - 2025
8.3.1 Germany
8.3.2 U.K.
8.3.3 France
8.3.4 Rest of Europe
8.4 Asia PacificRegional Market Estimates and Forecasts, 2012 - 2025
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Rest of Asia Pacific
8.5 Latin AmericaRegional Market Estimates and Forecasts, 2012 - 2025
8.5.1 Brazil
8.5.2 Argentina
8.6 Rest of the WorldRegional Market Estimates and Forecasts, 2012 - 2025

9 GLOBAL COMPETENT CELLS MARKETCOMPETITIVE LANDSCAPE
9.1 Overview
9.2 Company Market Share
9.3 Vendor Landscape
9.4 Key Development Strategies

10 COMPANY PROFILES
10.1 Thermo Fisher Scientific, Inc.
10.1.1 Overview
10.1.2 Financial Performance
10.1.3 Product Outlook
10.1.4 Key Developments

10.2 Merck KGaA
10.2.1 Overview
10.2.2 Financial Performance
10.2.3 Product Outlook
10.2.4 Key Developments

10.3 Promega Corporation
10.3.1 Overview
10.3.2 Financial Performance
10.3.3 Product Outlook
10.3.4 Key Developments

10.4 Takara Bio, Inc.
10.4.1 Overview
10.4.2 Financial Performance
10.4.3 Product Outlook
10.4.4 Key Developments

10.5 New England Biolabs, Inc.
10.5.1 Overview
10.5.2 Financial Performance
10.5.3 Product Outlook
10.5.4 Key Developments

10.6 Bio-Rad Laboratories, Inc.
10.6.1 Overview
10.6.2 Financial Performance
10.6.3 Product Outlook
10.6.4 Key Developments

10.7 Transgen Biotech, Inc.
10.7.1 Overview
10.7.2 Financial Performance
10.7.3 Product Outlook
10.7.4 Key Developments

10.8 Agilent Technologies, Inc.
10.8.1 Overview
10.8.2 Financial Performance
10.8.3 Product Outlook
10.8.4 Key Developments

10.9 Illumina, Inc.
10.9.1 Overview
10.9.2 Financial Performance
10.9.3 Product Outlook
10.9.4 Key Developments

10.10 Zymo Research
10.10.1 Overview
10.10.2 Financial Performance
10.10.3 Product Outlook
10.10.4 Key Developments

10.11 Qiagen N.V.
10.11.1 Overview
10.11.2 Financial Performance
10.11.3 Product Outlook
10.11.4 Key Developments
10.12 Genscript Biotech Corporation
10.12.1 Overview
10.12.2 Financial Performance
10.12.3 Product Outlook
10.12.4 Key Developments

10.13 Origene Technologies, Inc.
10.13.1 Overview
10.13.2 Financial Performance
10.13.3 Product Outlook
10.13.4 Key Developments

11 Appendix
11.1 Related Reports